Compare · ABT vs GOVX
ABT vs GOVX
Side-by-side comparison of Abbott Laboratories (ABT) and GeoVax Labs Inc. (GOVX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GOVX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $200.95B, about 42481.2x GOVX ($4.7M).
- Over the past year, ABT is down 11.8% and GOVX is down 96.7% - ABT leads by 85.0 points.
- ABT has hit the wire 8 times in the past 4 weeks while GOVX has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 5 for GOVX).
- Company
- Abbott Laboratories
- GeoVax Labs Inc.
- Price
- $116.11-0.50%
- $0.64-5.68%
- Market cap
- $200.95B
- $4.7M
- 1M return
- +11.04%
- -15.55%
- 1Y return
- -11.76%
- -96.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 0
- Recent ratings
- 25
- 5
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
GeoVax Labs Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against coronavirus (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Department of Defense; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies International, Inc.; Viamune, Inc.; Geneva Foundation; the University of California; and Leidos, Inc. GeoVax Labs, Inc. was incorporated in 2001 and is based in Smyrna, Georgia.
Latest ABT
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
- Abbott Laboratories filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Abbott reaches agreements to resolve a portion of litigation involving its specialty formulas for preterm infants
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- EXECUTIVE VICE PRESIDENT Morrone Louis H. sold $642,506 worth of Common shares without par value (5,850 units at $109.83), decreasing direct ownership by 8% to 70,724 units (SEC Form 4)
- Abbott Labs upgraded by Wolfe Research with a new price target
- Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis
- Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
Latest GOVX
- SEC Form 10-Q filed by GeoVax Labs Inc.
- GeoVax Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GeoVax Labs Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- SEC Form 4 filed by Director Spencer John N Jr
- SEC Form 4 filed by Director Morgan Jayne
- SEC Form 4 filed by Director Mcnally Robert T
- SEC Form 4 filed by Director Lemerond Nicole
- SEC Form 4 filed by Director Kollintzas Dean G
- SEC Form 4 filed by Director Chase Randal D
- SEC Form 4 filed by VP, Business Development Sharkey John W.